CA2253796C - Inhibition of matrix metalloproteases by acetylene containing compounds - Google Patents

Inhibition of matrix metalloproteases by acetylene containing compounds Download PDF

Info

Publication number
CA2253796C
CA2253796C CA002253796A CA2253796A CA2253796C CA 2253796 C CA2253796 C CA 2253796C CA 002253796 A CA002253796 A CA 002253796A CA 2253796 A CA2253796 A CA 2253796A CA 2253796 C CA2253796 C CA 2253796C
Authority
CA
Canada
Prior art keywords
biphenyl
oxo
alpha
compounds
butanoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002253796A
Other languages
English (en)
French (fr)
Other versions
CA2253796A1 (en
Inventor
Brian R. Dixon
Jinshan Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of CA2253796A1 publication Critical patent/CA2253796A1/en
Application granted granted Critical
Publication of CA2253796C publication Critical patent/CA2253796C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
CA002253796A 1996-05-15 1997-05-12 Inhibition of matrix metalloproteases by acetylene containing compounds Expired - Fee Related CA2253796C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64502896A 1996-05-15 1996-05-15
US08/645,028 1996-05-15
PCT/US1997/007921 WO1997043245A1 (en) 1996-05-15 1997-05-12 Inhibition of matrix metalloproteases by acetylene containing compounds

Publications (2)

Publication Number Publication Date
CA2253796A1 CA2253796A1 (en) 1997-11-20
CA2253796C true CA2253796C (en) 2003-10-28

Family

ID=24587368

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002253796A Expired - Fee Related CA2253796C (en) 1996-05-15 1997-05-12 Inhibition of matrix metalloproteases by acetylene containing compounds

Country Status (18)

Country Link
EP (1) EP0912496A1 (ja)
JP (1) JP3090957B2 (ja)
CN (1) CN1139570C (ja)
AR (1) AR007097A1 (ja)
AU (1) AU710759B2 (ja)
BR (1) BR9709077A (ja)
CA (1) CA2253796C (ja)
CO (1) CO5080759A1 (ja)
HN (1) HN1997000088A (ja)
HR (1) HRP970245B1 (ja)
ID (1) ID16910A (ja)
PA (1) PA8429301A1 (ja)
SV (1) SV1997000035A (ja)
TN (1) TNSN97084A1 (ja)
TW (1) TW381079B (ja)
WO (1) WO1997043245A1 (ja)
YU (1) YU18697A (ja)
ZA (1) ZA974031B (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
AR035478A1 (es) * 1999-01-27 2004-06-02 Wyeth Corp Acido amida-hidroxamico, acido acetilenico, beta-sulfonamido y fosfinico como inhibidores de la tace, uso de los mismos para la manufactura de un medicamento y composicion farmaceutica que los contiene
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
EP1031349A1 (en) * 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
US8765814B2 (en) * 2010-07-08 2014-07-01 Kaken Pharmaceutical Co., Ltd. N-hydroxyformamide derivative and medicament containing same
EP3126339A1 (de) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
US20170114049A1 (en) 2014-04-03 2017-04-27 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratory tract diseases
CA2944617A1 (en) 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784701A (en) * 1970-09-21 1974-01-08 American Cyanamid Co Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
DE2112716A1 (de) * 1971-03-17 1972-10-05 Thomae Gmbh Dr K Neue 4-(4-Biphenylyl)-4-oxobuttersaeuren,ihre Salze und ihre Ester
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
JP3090957B2 (ja) 2000-09-25
CA2253796A1 (en) 1997-11-20
HRP970245B1 (en) 2002-06-30
EP0912496A1 (en) 1999-05-06
HRP970245A2 (en) 1998-04-30
SV1997000035A (es) 1999-01-14
CN1139570C (zh) 2004-02-25
CO5080759A1 (es) 2001-09-25
PA8429301A1 (es) 2000-05-24
ID16910A (id) 1997-11-20
BR9709077A (pt) 1999-08-03
TW381079B (en) 2000-02-01
CN1225623A (zh) 1999-08-11
AU710759B2 (en) 1999-09-30
AR007097A1 (es) 1999-10-13
YU18697A (en) 1999-11-22
ZA974031B (en) 1998-02-19
TNSN97084A1 (fr) 2005-03-15
AU2938697A (en) 1997-12-05
WO1997043245A1 (en) 1997-11-20
JPH11511179A (ja) 1999-09-28
HN1997000088A (es) 1997-06-18

Similar Documents

Publication Publication Date Title
EP0790974B1 (en) Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitiors
US5925637A (en) Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids
AU714207B2 (en) Inhibition of matrix metalloproteases by 2-substituted-4- (4-substitutedphenyl)-4-oxobutyric acids
CA2253796C (en) Inhibition of matrix metalloproteases by acetylene containing compounds
US5968795A (en) Biaryl acetylenes as inhibitors of matrix metalloproteases
WO1997043239A9 (en) Inhibition of matrix metalloproteases by 2-substituted-4-(4-substitutedphenyl)-4-oxobutyric acids
US5863915A (en) Substituted 4-arylbutyric acid derivatives as matrix metalloprotease
CA2253795C (en) Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors
EP0907632B1 (en) Inhibition of matrix metalloproteases by substituted phenethyl compounds
CA2253869C (en) Substituted oxobutyric acids as matrix metalloprotease inhibitors
US5804581A (en) Inhibition of matrix metalloproteases by substituted phenalkyl compounds
US5932577A (en) Substituted oxobutyric acids as matrix metalloprotease inhibitors
CA2254750C (en) Inhibition of matrix metalloproteases by 2-(.omega.-aroylalkyl)-4-biaryl-oxobutyric acids
WO1997043238A9 (en) Substituted oxobutyric acids as matrix metalloprotease inhibitors
US5932763A (en) Inhibition of matrix metalloproteases by 2-(ω-arolalkyl)-4-biaryl-4-oxobutyric acids

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed